Longitudinal assessment of cardiac diastolic function in HIV-infected patients

International Journal of STD and AIDS

Volumn 23, Issue 2, 2012, Pages 105-110

  Blaylock, J M ^a   Byers, D K ^b   Gibbs, B T ^a   Nayak, G ^b   Ferguson, M ^b   Tribble, D R ^b,c   Porter, C ^d   Decker, C F ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c Uniformed Services University ^*

^d NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

Cardiac; Cardiovascular disease; Diastolic dysfunction; Echocardiography; HIV infection

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM EXAMINATION; CD4 LYMPHOCYTE COUNT; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DISEASE DURATION; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HEART FUNCTION; HEART LEFT VENTRICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTENSION; INFECTION RISK; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION;

ADULT; DIASTOLE; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASES; HIV INFECTIONS; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SYSTOLE;

EID: 84858204780     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2011.011099     Document Type: Article

References (42)

1. ART-CC. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-99
2. ART-CC. Cause of death in HIV-1 infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 cohort studies. Clin Infect Dis 2010;50:1387-96
3. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2007. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2009
4. Riddler SA, Smith E, Cole SR. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289:2978-82
5. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors in patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92:2506-12
6. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors for HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179-93
7. Friss-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35
8. El Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral therapy. N Engl J Med 2006;355:2283-96
9. Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008;13:177-87
10. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naïve subjects before and after starting potent antiretroviral therapy. J Am Col Cardiol 2008;52:569-76
11. Mu H, Chai H, Lin PH, et al. Current update on HIV-associated vascular disease and endothelial dysfunction. World J Surg 2007;31:632-43
12. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202
13. Nayak G, Ferguson M, Tribble DR, et al. Cardiac diastolic dysfunction is prevalent in HIV-infected patients. AIDS Patient Care STDS 2009;23:231-38
14. Hsue PY, Hunt PW, Ho JE, et al. Impact of HIV infection on diastolic dysfunction and left ventricular mass. Circ Heart Fail 2010;3:132-39
15. Reinsch N, Neuhaus K, Esser S, et al. Prevalence of cardiac diastolic dysfunction in HIV-infected patients: results of the HIV-HEART study. HIV Clin Trials 2010;11:156-62
16. Schuster I, Thoni GJ, Edérhy S, et al. Subclinical cardiac abnormalities in human immunodeficiency virus-infected men receiving antiretroviral therapy. Am J Cardiol 2008;101:1213-17
17. Mondy KE, Gottdiener J, Overton ET, et al. High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy. Clin Infect Dis 2011;52:378-86
18. Fischer M, Baessler A, Hense HW, et al. Prevalence of left ventricular diastolic dysfunction in the community. Eur Heart J 2003;24:320-28
19. Kuznetsova T, Herbots L, Lopez B, et al. Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail 2009;2:105-12
20. Centers for Disease Control and Prevention. Update: trends in AIDS diagnosis and reporting under the expanded surveillance definition for adolescents and adults - United States, 1993. MMWR Morb Mortal Wkly Rep 1994;43:826-31
21. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-29
22. Otto C. Transthoracic views, normal anatomy, and flowpatterns. In: OttoC(ed). Textbook of Clinical Echocardiography. 3rd edn. Philadelphia: Elsevier Saunders, 2004: 30-69
23. Mueller J, Stauffer A, Jaussi J, et al. Subjective visual echocardiographic estimate of left ventricular ejection fraction as an alternative to conventional echocardiographic methods: comparison with contrast angiography. Clin Cardiol 1999;14:898-907
24. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47
25. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III). National Heart, Lung, and Blood Institute, National Institute of Health, 2002
26. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinology medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(Suppl 1):1-66
27. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. US Department of Health and Human Services, National Institute of Health, 2004
28. Tong W, Lima JA, Meng Q, et al. Long-term cocaine use is related to cardiac diastolic dysfunction in an African-American population in Baltimore, Maryland. Int J Cardiol 2004;97:25-28
29. Ito H, Yeo K, Wijetunga M, et al. A comparison of echocardiographic findings in young adults with cardiomyopathy: with and without a history of methamphetamine abuse. Clin Cardiol 2009;32:E18-22
30. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-48
31. D:A:D Study Group, Sabin CA, Worm SW, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371:1417-26
32. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010;201:318-30
33. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009;51:20-28
34. Long S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 2010;170:1228-38
35. Ross AC, Rizk N, O'Riordan MA, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009;49:1119-27
36. Ross AC, Armentrout R, O'Riordan MA, et al. Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr 2008;49:499-506
37. Kaplan RC, Kingsley LA, Gange SJ, et al. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008;22:1615-24
38. Byers DK, Nayak G, Ferguson M, et al. Prevalence of pulmonary hypertension in asymptomatic HIV-infected patients receiving antiretroviral therapy. [abstract H-2312] In: Program and Abstracts of the 46th Annual Meeting of the Infectious Diseases Society of America. Washington, DC, 2008
39. Cicalini S, Chinello P, Lisena F, Petrosillo N. HIV-Associated Pulmonary Hypertension: to Screen or Not to Screen. [abstract P999] In: 18th European Congress of Clinical Microbiology and Infectious Diseases. Barcelona, 2008
40. Benjamin EJ, Levy D, Anderson KM, et al. Determinants of Doppler indexes of left ventricular diastolic function in normal subjects [The Framingham Heart Study]. Am J Cardiol 1992;70:508-15
41. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. New Engl J Med 2006;355:251-59
42. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction: a population-based study. J Am Coll Cardiol 2010;55:300-05